[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Promis Neurosciences Inc (PMN)

Promis Neurosciences Inc (PMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 130,121
  • Shares Outstanding, K 8,968
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,720 K
  • EBIT $ -43 M
  • EBITDA $ -43 M
  • 60-Month Beta -0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.22
  • Number of Estimates 3
  • High Estimate $-1.13
  • Low Estimate $-1.29
  • Prior Year $-6.00
  • Growth Rate Est. (year over year) +79.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.25 +31.56%
on 07/27/26
17.25 -14.20%
on 07/28/26
+2.60 (+21.31%)
since 07/24/26
3-Month
9.09 +62.82%
on 06/05/26
17.25 -14.20%
on 07/28/26
+3.82 (+34.79%)
since 05/22/26
52-Week
6.27 +136.04%
on 11/28/25
27.40 -45.99%
on 03/05/26
+1.40 (+10.47%)
since 08/22/25

Most Recent Stories

More News
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.68 (+2.34%)
SER : 2.63 (-8.36%)
GANX : 2.00 (-0.25%)
BIOA : 9.38 (-1.05%)
OSTX : 1.5500 (-2.52%)
VTVT : 33.89 (+1.91%)
MASS : 10.92 (+2.25%)
PYPD : 4.99 (-2.25%)
TKNO : 7.34 (-0.27%)
OVID : 2.82 (+0.71%)
MDCX : 0.2574 (-5.30%)
EQ : 2.20 (-4.76%)
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

  Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences to Participate in Upcoming Conferences in June

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease...

PMN : 14.80 (+2.00%)
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early...

PMN : 14.80 (+2.00%)

Business Summary

ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330,...

See More

Key Turning Points

3rd Resistance Point 16.66
2nd Resistance Point 16.06
1st Resistance Point 15.43
Last Price 14.80
1st Support Level 14.20
2nd Support Level 13.60
3rd Support Level 12.97

See More

52-Week High 27.40
Fibonacci 61.8% 19.33
Fibonacci 50% 16.83
Last Price 14.80
Fibonacci 38.2% 14.34
52-Week Low 6.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.